原著
2017年
Kotaki R, Higuchi H, Ogiya D, Katahira Y, Kurosaki N, Yukihira N, Ogata J, Yamamoto H, Mohamad Alba S, Azhim A, Kitajima T, Inoue S, Morishita K, Ono K, Koyama-Nasu R, Kotani A. Imbalanced expression of polycistronic miRNA in acute myeloid leukemia. Int J Hematol. 2017 Dec;106(6):811-819.
Permatasari HK, Nakahata S, Ichikawa T, Morishita K. BCL11B is frequently downregulated in HTLV-1-infected T-cells through Tax-mediated proteasomal degradation. Biochem Biophys Res Commun. 2017 Aug 26;490(3):1086-1092.
Komohara Y, Ma C, Yano H, Pan C, Horlad H, Saito Y, Ohnishi K, Fujiwara Y, Okuno Y, Nosaka K, Shimosaki S, Morishita K, Matsuoka M, Wakayama T, Takeya M. Cell adhesion molecule-1 (CADM1) expressed on adult T-cell leukemia/lymphoma cells is not involved in the interaction with macrophages. J Clin Exp Hematop. 2017 Jul 5;57(1):15-20.
Tamura T*, Ichikawa T* (*equally contributed), Nakahata S, Kondo Y, Tagawa Y, Yamamoto K, Nagai K, Baba T, Yamaguchi R, Futakuchi M, Yamashita Y, Morishita K. Loss of NDRG2 Expression Confers Oral Squamous Cell Carcinoma with Enhanced Metastatic Potential. Cancer Res. 2017 May 1;77(9):2363-2374.
2016年
Chang YT, Shu CL, Lai JY, Lin CY, Chuu CP, Morishita K, Ichikawa T, Jessberger R, Fukui Y. SWAP-70 contributes to spontaneous transformation of mouse embryo fibroblasts. Exp Cell Res. 2016 Jul 15;345(2):150-7.
Shimosaki S, Nakahata S, Ichikawa T, Kitanaka A, Kameda T, Hidaka T, Kubuki Y, Kurosawa G, Zhang L, Sudo Y, Shimoda K, Morishita K. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma. Biochem Biophys Res Commun. 2017 Mar 25;485(1):144-151.
Manachai N, Saito Y, Nakahata S, Bahirvani AG, Osato M, Morishita K. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia. Biochem Biophys Res Commun. 2017 Jan 22;482(4):994-1000.
2015年
Ichikawa T, Nakahata S, Tamura T, Manachai N, Morishita K. The loss of NDRG2 expression improves depressive behavior through increased phosphorylation of GSK3β. Cell Signal. 2015 Oct;27(10):2087-98.
Shigemura T, Shiohara M, Kato M, Furuta S, Kaneda K, Morishita K, Hasegawa H, Fujii M, Gorlach A, Koike K, Kamata T. Superoxide-Generating Nox5α Is Functionally Required for the Human T-Cell Leukemia Virus Type 1-Induced Cell Transformation Phenotype. J Virol. 2015 Sep;89(17):9080-9.
Ichikawa T, Nakahata S, Fujii M, Iha H, Morishita K. Loss of NDRG2 enhanced activation of the NF-κB pathway by PTEN and NIK phosphorylation for ATL and other cancer development. Sci Rep. 2015 Aug 13;5:12841.
Hiyoshi M, Okuma K, Tateyama S, Takizawa K, Saito M, Kuramitsu M, Araki K, Morishita K, Okada S, Yamamoto N, Biragyn A, Yamaguchi K, Hamaguchi I. Furin-dependent CCL17-fused recombinant toxin controls HTLV-1 infection by targeting and eliminating infected CCR4-expressing cells in vitro and in vivo.
Retrovirology. 2015 Aug 20;12:73.
2014年
Yamasaki M, Nishimura M, Sakakibara Y, Suiko M, Morishita K, Nishiyama K. Delta-tocotrienol induces apoptotic cell death via depletion of intracellular squalene in ED40515 cells. Food Funct. 2014 Nov;5(11):2842-9.
Miyauchi S, Umekita K, Hidaka T, Umeki K, Aratake Y, Takahashi N, Sawaguchi A, Nakatake A, Morinaga I, Morishita K, Okayama A. Increased plasma lactoferrin levels in leucocytapheresis therapy in patients with rheumatoid arthritis. Rheumatology (Oxford). 2014 Nov;53(11):1966-72.
Nagai K, Nakahata S, Shimosaki S, Tamura T, Kondo Y, Baba T, Taki T, Taniwaki M, Kurosawa G, Sudo Y, Okada S, Sakoda S, Morishita K. Development of a complete human anti-human transferrin receptor C antibody as a novel marker of oral dysplasia and oral cancer. Cancer Med. 2014 Aug;3(4):1085-99.
Nakahata S*, Ichikawa T* (*equally contributed), Maneesaay P, Saito Y, Nagai K, Tamura T, Manachai N, Yamakawa N, Hamasaki M, Kitabayashi I, Arai Y, Kanai Y, Taki T, Abe T, Kiyonari H, Shimoda K, Ohshima K, Horii A, Shima H, Taniwaki M, Yamaguchi R, Morishita K. Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. Nat Commun. 2014 Feb 26;5:3393.
2013年
Kai H, Akamatsu E, Torii E, Kodama H, Yukizaki C, Akagi I, Ino H, Sakakibara Y, Suiko M, Yamamoto I, Okayama A, Morishita K, Kataoka H, Matsuno K. Identification of a Bioactive Compound against Adult T-cell Leukaemia from Bitter Gourd Seeds. Plants (Basel). 2013 Dec 27;3(1):18-26.
Yamamura A, Miura K, Karasawa H, Morishita K, Abe K, Mizuguchi Y, Saiki Y, Fukushige S, Kaneko N, Sase T, Nagase H, Sunamura M, Motoi F, Egawa S, Shibata C, Unno M, Sasaki I, Horii A. Suppressed expression of NDRG2 correlates with poor prognosis in pancreatic cancer. Biochem Biophys Res Commun. 2013 Nov 8;441(1):102-7.
Saito Y, Kaneda K, Suekane A, Ichihara E, Nakahata S, Yamakawa N, Nagai K, Mizuno N, Kogawa K, Miura I, Itoh H, Morishita K. Maintenance of the hematopoietic stem cell pool in bone marrow niches by EVI1-regulated GPR56. Leukemia. 2013 Aug;27(8):1637-49.
Ikebe E, Kawaguchi A, Tezuka K, Taguchi S, Hirose S, Matsumoto T, Mitsui T, Senba K, Nishizono A, Hori M, Hasegawa H, Yamada Y, Ueno T, Tanaka Y, Sawa H, Hall W, Minami Y, Jeang KT, Ogata M, Morishita K, Hasegawa H, Fujisawa J, Iha H. Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice. Blood Cancer J. 2013 Aug 16;3:e132.
Yamasaki M, Mine Y, Nishimura M, Fujita S, Sakakibara Y, Suiko M, Morishita K, Nishiyama K. Genistein induces apoptotic cell death associated with inhibition of the NF-κB pathway in adult T-cell leukemia cells. Cell Biol Int. 2013 Jul;37(7):742-7.
Sugie S, Mukai S, Tsukino H, Toda Y, Yamauchi T, Nishikata I, Kuroda Y, Morishita K, Kamoto T. Increased plasma caveolin-1 levels are associated with progression of prostate cancer among Japanese men. Anticancer Res. 2013 May;33(5):1893-7.
Nagahama K, Eto N, Sakakibara Y, Matsushita Y, Sugamoto K, Morishita K, Suiko M. Oligomeric proanthocyanidins from rabbiteye blueberry leaves inhibits the proliferation of human T-cell lymphotropic virus type 1-associated cell lines via apoptosis and cell cycle arrest. Journal of Functional Foods 2014 Jan;6(1):356-66.
2012年
Nakahata S, Saito Y, Marutsuka K, Hidaka T, Maeda K, Hatakeyama K, Shiraga T, Goto A, Takamatsu N, Asada Y, Utsunomiya A, Okayama A, Kubuki Y, Shimoda K, Ukai Y, Kurosawa G, Morishita K. Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma. Leukemia. 2012 Jun;26(6):1238-46.
Ueno S, Umeki K, Takajo I, Nagatomo Y, Kusumoto N, Umekita K, Morishita K, Okayama A. Proviral loads of human T-lymphotropic virus Type 1 in asymptomatic carriers with different infection routes. Int J Cancer. 2012 May 15;130(10):2318-26. doi: 10.1002/ijc.26289.
Kondo Y, Nagai K, Nakahata S, Saito Y, Ichikawa T, Suekane A, Taki T, Iwakawa R, Enari M, Taniwaki M, Yokota J, Sakoda S, Morishita K. Overexpression of the DNA sensor proteins, absent in melanoma 2 and interferon-inducible 16, contributes to tumorigenesis of oral squamous cell carcinoma with p53 inactivation. Cancer Sci. 2012 Apr;103(4):782-90.
2011年
Ichihara E, Kaneda K, Saito Y, Yamakawa N, Morishita K. Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1(high) leukemia cells. Biochem Biophys Res Commun. 2011 Dec 16;416(3-4):239-45.
Roy BC, Kohno T, Iwakawa R, Moriguchi T, Kiyono T, Morishita K, Sanchez-Cespedes M, Akiyama T, Yokota J. Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells. Lung Cancer. 2010 Nov;70(2):136-45.
Yamakawa N, Kaneda K, Saito Y, Ichihara E, Morishita K. The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia. PLoS One. 2012;7(1):e30706.
Nishikata I, Nakahata S, Saito Y, Kaneda K, Ichihara E, Yamakawa N, Morishita K. Sumoylation of MEL1S at lysine 568 and its interaction with CtBP facilitates its repressor activity and the blockade of G-CSF-induced myeloid differentiation. Oncogene. 2011 Oct 6;30(40):4194-207.
Saito Y, Nakahata S, Yamakawa N, Kaneda K, Ichihara E, Suekane A, Morishita K. CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression. Leukemia. 2011 Jun;25(6):921-31.
Takenouchi H, Umeki K, Sasaki D, Yamamoto I, Nomura H, Takajo I, Ueno S, Umekita K, Kamihira S, Morishita K, Okayama A. Defective human T-lymphotropic virus type 1 provirus in asymptomatic carriers. Int J Cancer. 2011 Mar 15;128(6):1335-43.
2010年
Yamamoto I, Takajo I, Umeki K, Morishita K, Hatakeyama K, Kataoka H, Nomura H, Okayama A. Multiple integrations of human T-lymphotropic virus type 1 proviruses in the engrafted cells from the asymptomatic carriers in NOD/SCID/gammacnull mice. Intervirology. 2010;53(4):229-39.
Yamasaki M, Mukai A, Ohba M, Mine Y, Sakakibara Y, Suiko M, Morishita K, Nishiyama K. Genistein induced apoptotic cell death in adult T-cell leukemia cells through estrogen receptors. Biosci Biotechnol Biochem. 2010;74(10):2113-5.
Furuta H, Kondo Y, Nakahata S, Hamasaki M, Sakoda S, Morishita K. NDRG2 is a candidate tumor-suppressor for oral squamous-cell carcinoma. Biochem Biophys Res Commun. 2010 Jan 22;391(4):1785-91.
Watanabe M, Nakahata S, Hamasaki M, Saito Y, Kawano Y, Hidaka T, Yamashita K, Umeki K, Taki T, Taniwaki M, Okayama A, Morishita K. Downregulation of CDKN1A in adult T-cell leukemia/lymphoma despite overexpression of CDKN1A in human T-lymphotropic virus 1-infected cell lines. J Virol. 2010 Jul;84(14):6966-77.
Nakahata S, Yamazaki S, Nakauchi H, Morishita K. Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma. Oncogene. 2010 Jul 22;29(29):4157-69.
Shimahara A, Yamakawa N, Nishikata I, Morishita K. Acetylation of lysine 564 adjacent to the C-terminal binding protein-binding motif in EVI1 is crucial for transcriptional activation of GATA2. J Biol Chem. 2010 May 28;285(22):16967-77.
2009年
Nakahata S, Saito Y, Hamasaki M, Hidaka T, Arai Y, Taki T, Taniwaki M, Morishita K. Alteration of enhancer of polycomb 1 at 10p11.2 is one of the genetic events leading to development of adult T-cell leukemia/lymphoma. Genes Chromosomes Cancer. 2009 Sep;48(9):768-76.
Takahata M, Inoue Y, Tsuda H, Imoto I, Koinuma D, Hayashi M, Ichikura T, Yamori T, Nagasaki K, Yoshida M, Matsuoka M, Morishita K, Yuki K, Hanyu A, Miyazawa K, Inazawa J, Miyazono K, Imamura T. SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells. J Biol Chem. 2009 Jan 30;284(5):3334-44.
2008年
Dewan MZ, Takamatsu N, Hidaka T, Hatakeyama K, Nakahata S, Fujisawa J, Katano H, Yamamoto N, Morishita K. Critical role for TSLC1 expression in the growth and organ infiltration of adult T-cell leukemia cells in vivo. J Virol. 2008 Dec;82(23):11958-63.
Ishida Y, Yamashita K, Sasaki H, Takajou I, Kubuki Y, Morishita K, Tsubouchi H, Okayama A. Activation of complement system in adult T-cell leukemia (ATL) occurs mainly through lectin pathway: a serum proteomic approach using mass spectrometry. Cancer Lett. 2008 Nov 18;271(1):167-77.
Hidaka T*, Nakahata S*, Hatakeyama K* (*equally contributed), Hamasaki M, Yamashita K, Kohno T, Arai Y, Taki T, Nishida K, Okayama A, Asada Y, Yamaguchi R, Tsubouchi H, Yokota J, Taniwaki M, Higashi Y, Morishita K. Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma. Blood. 2008 Jul 15;112(2):383-93.
2007年
Takajo I, Umeki K, Morishita K, Yamamoto I, Kubuki Y, Hatakeyama K, Kataoka H, Okayama A. Engraftment of peripheral blood mononuclear cells from human T-lymphotropic virus type 1 carriers in NOD/SCID/gammac(null) (NOG) mice. Int J Cancer. 2007 Nov 15;121(10):2205-11.
Yamasaki M, Fujita S, Ishiyama E, Mukai A, Madhyastha H, Sakakibara Y, Suiko M, Hatakeyama K, Nemoto T, Morishita K, Kataoka H, Tsubouchi H, Nishiyama K. Soy-derived isoflavones inhibit the growth of adult T-cell leukemia cells in vitro and in vivo. Cancer Sci. 2007 Nov;98(11):1740-6.
2005年
Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, Mucenski ML, Suda T, Morishita K. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J. 2005 Jun 1;24(11):1976-87.
Mead PE, Parganas E, Ohtsuka S, Morishita K, Gamer L, Kuliyev E, Wright CV, Ihle JN. Evi-1 expression in Xenopus. Gene Expr Patterns. 2005 Jun;5(5):601-8.
Furukoji E, Matsumoto M, Yamashita A, Yagi H, Sakurai Y, Marutsuka K, Hatakeyama K, Morishita K, Fujimura Y, Tamura S, Asada Y. Adenovirus-mediated transfer of human placental ectonucleoside triphosphate diphosphohydrolase to vascular smooth muscle cells suppresses platelet aggregation in vitro and arterial thrombus formation in vivo. Circulation. 2005 Feb 15;111(6):808-15.
Sasaki H, Nishikata I, Shiraga T, Akamatsu E, Fukami T, Hidaka T, Kubuki Y, Okayama A, Hamada K, Okabe H, Murakami Y, Tsubouchi H, Morishita K. Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia. Blood. 2005 Feb 1;105(3):1204-13.
2004年
Yoshida M, Nosaka K, Yasunaga J, Nishikata I, Morishita K, Matsuoka M. Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells. Blood. 2004 Apr 1;103(7):2753-60.
Hashida S, Kitamura K, Nagatomo Y, Shibata Y, Imamura T, Yamada K, Fujimoto S, Kato J, Morishita K, Eto T. Development of an ultrasensitive enzyme immunoassay for human proadrenomedullin N-terminal 20 peptide and direct measurement of two molecular forms of PAMP in plasma from healthy subjects and patients with cardiovascular disease. Clin Biochem. 2004 Jan;37(1):14-21.
2003年
Nishikata I, Sasaki H, Iga M, Tateno Y, Imayoshi S, Asou N, Nakamura T, Morishita K. A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation. Blood. 2003 Nov 1;102(9):3323-32.
Kurokawa M, Hidaka T, Sasaki H, Nishikata I, Morishita K, Setoyama M. Analysis of hepatitis C virus (HCV) RNA in the lesions of lichen planus in patients with chronic hepatitis C: detection of anti-genomic- as well as genomic-strand HCV RNAs in lichen planus lesions. J Dermatol Sci. 2003 Jun;32(1):65-70.
Cao YN, Kitamura K, Ito K, Kato J, Hashida S, Morishita K, Eto T. Glycine-extended adrenomedullin exerts vasodilator effect through amidation in the rat aorta. Regul Pept. 2003 May 15;113(1-3):109-14.
Yamaga J, Hashida S, Kitamura K, Tokashiki M, Aoki T, Inatsu H, Ishikawa N, Kangawa K, Morishita K, Eto T. Direct measurement of glycine-extended adrenomedullin in plasma and tissue using an ultrasensitive immune complex transfer enzyme immunoassay in rats. Hypertens Res. 2003 Feb;26 Suppl:S45-53.
2002年以前
Iga M, Matsuda Z, Okayama A, Sugiura W, Hashida S, Morishita K, Nagai Y, Tsubouchi H. Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation. J Virol Methods. 2002 Oct;106(1):25-37.
Shimizu S, Nagasawa T, Katoh O, Komatsu N, Yokota J, Morishita K. EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in UT-7/GM cells induces megakaryocyte differentiation. Biochem Biophys Res Commun. 2002 Apr 5;292(3):609-16.
Eguchi M, Eguchi-Ishimae M, Seto M, Morishita K, Suzuki K, Ueda R, Ueda K, Kamada N, Greaves M. GPHN, a novel partner gene fused to MLL in a leukemia with t(11;14)(q23;q24). Genes Chromosomes Cancer. 2001 Nov;32(3):212-21.
Mochizuki N, Shimizu S, Nagasawa T, Tanaka H, Taniwaki M, Yokota J, Morishita K. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood. 2000 Nov 1;96(9):3209-14.
Inoue K, Kohno T, Takakura S, Morishita K, Takita J, Hayashi Y, Mizoguchi H, Yokota J. Alterations of the PPP1R3 gene in hematological malignancies. Int J Oncol. 2000 Oct;17(4):717-21.
Shimizu S, Suzukawa K, Kodera T, Nagasawa T, Abe T, Taniwaki M, Yagasaki F, Tanaka H, Fujisawa S, Johansson B, Ahlgren T, Yokota J, Morishita K. Identification of breakpoint cluster regions at 1p36.3 and 3q21 in hematologic malignancies with t(1;3)(p36;q21). Genes Chromosomes Cancer. 2000 Mar;27(3):229-38.
Yamamoto K, Nagata K, Tsurukubo Y, Morishita K, Hamaguchi H. A novel translocation t(3;22)(q21;q11) involving 3q21 in myelodysplastic syndrome-derived overt leukemia with thrombocytosis. Leuk Res. 2000 May;24(5):453-7.
Kodera T, Kohno T, Takakura S, Morishita K, Hamaguchi H, Hayashi Y, Sasaki T, Yokota J. Microsatellite instability in lymphoid leukemia and lymphoma cell lines but not in myeloid leukemia cell lines. Genes Chromosomes Cancer. 1999 Nov;26(3):267-9.
Suzukawa K, Kodera T, Shimizu S, Nagasawa T, Asou H, Kamada N, Taniwaki M, Yokota J, Morishita K. Activation of EVI1 transcripts with chromosomal translocation joining the TCRVbeta locus and the EVI1 gene in human acute undifferentiated leukemia cell line (Kasumi-3) with a complex translocation of der(3)t(3;7;8). Leukemia. 1999 Sep;13(9):1359-66.
Kazama H, Kodera T, Shimizu S, Mizoguchi H, Morishita K. Ecotropic viral integration site-1 is activated during, and is sufficient for, neuroectodermal P19 cell differentiation. Cell Growth Differ. 1999 Aug;10(8):565-73.
Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sato Y, Kudoh S, Tanaka K, Setoyama M, Nagamura F, Asano S, Kamada N. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood. 1999 Feb 15;93(4):1355-63.
Igarashi T, Shimizu S, Morishita K, Ohtsu T, Itoh K, Minami H, Fujii H, Sasaki Y, Mukai K. Acute myelogenous leukemia with monosomy 7, inv(3) (q21q26), involving activated EVI 1 gene occurring after a complete remission of lymphoblastic lymphoma: a case report. Jpn J Clin Oncol. 1998 Nov;28(11):688-95.
Taki T, Shibuya N, Taniwaki M, Hanada R, Morishita K, Bessho F, Yanagisawa M, Hayashi Y. ABI-1, a human homolog to mouse Abl-interactor 1, fuses the MLL gene in acute myeloid leukemia with t(10;11)(p11.2;q23). Blood. 1998 Aug 15;92(4):1125-30.
Iwase S, Furukawa Y, Horiguchi-Yamada J, Nemoto T, Takahara S, Kawano T, Sekikawa T, Ito K, Yamazaki Y, Kikuchi J, Morishita K, Yamada H. A novel variant of acute myelomonocytic leukemia carrying t(3;12)(q26;p13) with characteristics of 3q21q26 syndrome. Int J Hematol. 1998 Jun;67(4):361-8.
Hamaguchi H, Suzukawa K, Nagata K, Yamamoto K, Yagasaki F, Morishita K. Establishment of a novel human myeloid leukaemia cell line (HNT-34) with t(3;3)(q21;q26), t(9;22)(q34;q11) and the expression of EVI1 gene, P210 and P190 BCR/ABL chimaeric transcripts from a patient with AML after MDS with 3q21q26 syndrome. Br J Haematol. 1997 Aug;98(2):399-407.
Suzukawa K, Taki T, Abe T, Asoh H, Kamada N, Yokota J, Morishita K. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with
inv(3)(q21q26). Genomics. 1997 Jun 1;42(2):356-60.
Arai K, Morishita K, Shinmura K, Kohno T, Kim SR, Nohmi T, Taniwaki M, Ohwada S, Yokota J. Cloning of a human homolog of the yeast OGG1 gene that is involved in the repair of oxidative DNA damage. Oncogene. 1997 Jun 12;14(23):2857-61.
Taki T, Hayashi Y, Taniwaki M, Seto M, Ueda R, Hanada R, Suzukawa K, Yokota J, Morishita K. Fusion of the MLL gene with two different genes, AF-6 and AF-5alpha, by a complex translocation involving chromosomes 5, 6, 8 and 11 in infant leukemia. Oncogene. 1996 Nov 21;13(10):2121-30.
Adachi J, Ookawa K, Shiseki M, Okazaki T, Tsuchida S, Morishita K, Yokota J. Induction of apoptosis but not G1 arrest by expression of the wild-type p53 gene in small cell lung carcinoma. Cell Growth Differ. 1996 Jul;7(7):879-86.
Asou H, Eguchi M, Suzukawa K, Morishita K, Tanaka K, Date M, Hamamoto K, Kamada N. Establishment of a myeloid leukaemia cell line (Kasumi-4) with t(9;22;11)(q34;q11;q13), inv(3)(q21q26) and the EVI1 gene activation from a patient with chronic myelogenous leukaemia in blast crisis. Br J Haematol. 1996 Apr;93(1):68-74.
Asou H, Suzukawa K, Kita K, Nakase K, Ueda H, Morishita K, Kamada N. Establishment of an undifferentiated leukemia cell line (Kasumi-3) with t(3;7)(q27;q22) and activation of the EVI1 gene. Jpn J Cancer Res. 1996 Mar;87(3):269-74.
Suzukawa K, Satoh H, Taniwaki M, Yokota J, Morishita K. The human thrombopoietin gene is located on chromosome 3q26.33-q27, but is not transcriptionally activated in leukemia cells with 3q21 and 3q26 abnormalities (3q21q26 syndrome). Leukemia. 1995 Aug;9(8):1328-31.
Morishita K, Suzukawa K, Taki T, Ihle JN, Yokota J. EVI-1 zinc finger protein works as a transcriptional activator via binding to a consensus sequence of GACAAGATAAGATAAN1-28 CTCATCTTC. Oncogene. 1995 May 18;10(10):1961-7.
Ohyashiki K, Ohyashiki JH, Fujieda H, Shimamoto T, Kawakubo K, Nakazawa S, Suzukawa K, Morishita K, Toyama K. EVI1 expression associated with a 3q26 anomaly in a leukemia cell line derived from the blast crisis of chronic myeloid leukemia. Leukemia. 1994 Dec;8(12):2169-73.
Levy ER, Parganas E, Morishita K, Fichelson S, James L, Oscier D, Gisselbrecht S, Ihle JN, Buckle VJ. DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome. Blood. 1994 Mar 1;83(5):1348-54.
Kohno T, Morishita K, Takano H, Shapiro DN, Yokota J. Homozygous deletion at chromosome 2q33 in human small-cell lung carcinoma identified by arbitrarily primed PCR genomic fingerprinting. Oncogene. 1994 Jan;9(1):103-8.
Delwel R, Funabiki T, Kreider BL, Morishita K, Ihle JN. Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA. Mol Cell Biol. 1993 Jul;13(7):4291-300.
Morishita K, Parganas E, William CL, Whittaker MH, Drabkin H, Oval J, Taetle R, Valentine MB, Ihle JN. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3937-41.
Morishita K, Parganas E, Matsugi T, Ihle JN. Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol Cell Biol. 1992 Jan;12(1):183-9.
Morishita K, Parganas E, Parham DM, Matsugi T, Ihle JN. The Evi-1 zinc finger myeloid transforming gene is normally expressed in the kidney and in developing oocytes. Oncogene. 1990 Sep;5(9):1419-23.
Morishita K, Parganas E, Douglass EC, Ihle JN. Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts. Oncogene. 1990 Jul;5(7):963-71.
Morishita K, Parganas E, Bartholomew C, Sacchi N, Valentine MB, Raimondi SC, Le Beau MM, Ihle JN. The human Evi-1 gene is located on chromosome 3q24-q28 but is not rearranged in three cases of acute nonlymphocytic leukemias containing t(3;5)(q25;q34) translocations. Oncogene Res. 1990;5(3):221-31.
Matsugi T, Morishita K, Ihle JN. Identification, nuclear localization, and DNA-binding activity of the zinc finger protein encoded by the Evi-1 myeloid transforming gene. Mol Cell Biol. 1990 Mar;10(3):1259-64.
Bartholomew C, Morishita K, Askew D, Buchberg A, Jenkins NA, Copeland NG, Ihle JN. Retroviral insertions in the CB-1/Fim-3 common site of integration activate expression of the Evi-1 gene. Oncogene. 1989 May;4(5):529-34.
Weinstein Y, Morishita K, Cleveland JL, Ihle JN. Interleukin 3 (IL-3) induces transcription from nonrearranged T cell receptor gamma loci in IL-3-dependent cell lines. J Exp Med. 1989 Jun 1;169(6):2059-71.
Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell. 1988 Sep 9;54(6):831-40.
Matsushima K, Morishita K, Yoshimura T, Lavu S, Kobayashi Y, Lew W, Appella E, Kung HF, Leonard EJ, Oppenheim JJ. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med. 1988 Jun 1;167(6):1883-93.
Morishita K, Tsuchiya M, Asano S, Kaziro Y, Nagata S. Chromosomal gene structure of human myeloperoxidase and regulation of its expression by granulocyte colony-stimulating factor. J Biol Chem. 1987 Nov 5;262(31):15208-13.
Morishita K, Kubota N, Asano S, Kaziro Y, Nagata S. Molecular cloning and characterization of cDNA for human myeloperoxidase. J Biol Chem. 1987 Mar 15;262(8):3844-51.
Morishita K, Asano S, Fujii H, Yokota J, Kodo H, Miwa S. Biochemical comparison of myeloperoxidase of leukemic myeloblasts and normal neutrophilic granulocytes. J Appl Biochem. 1984 Oct-Dec;6(5-6):271-7.
Morishita K, Asano S, Takuwa N, Yokota J, Ieki R, Kodo H, Nakayama E, Enomoto Y, Watanabe Y, Miwa S. An atypical case of megakaryoblastic leukaemia. Scand J Haematol. 1984 May;32(5):449-51.
Shinohara T, Takuwa N, Morishita K, Ieki R, Yokota J, Nakayama E, Asano S, Miwa S. Chronic myelomonocytic leukemia with a chromosome abnormality (46,XY,20q-) in all dividing myeloid cells: evidence for clonal origin in a multipotent stem cell common to granulocyte, monocyte, erythrocyte, and thrombocyte. Am J Hematol. 1983 Nov;15(3):289-93.
Yokota J, Asano S, Teshima S, Morishita K, Iwamoto A, Yoshikura H, Miwa S. Alterations of polypeptide composition of mature granulocytes obtained from patients with chronic myelogenous leukemia. Blood. 1982 Feb;59(2):443-6.
総説
中畑新吾、森下和広：PTENリン酸化調節からみえたがん抑制遺伝子NDRG2の新たな機能 生化学 89(6):877-880 (2017)
中畑新吾、森下和広：ATL細胞におけるシグナル伝達機構と治療標的 血液内科 74:327-333 (2017)
中畑新吾、森下和広：成人T細胞白血病・リンパ腫の発症機構 造血器腫瘍アトラス〈第5版〉345-352 (2016)
中畑新吾、森下和広：成人T細胞白血病/リンパ腫(ATLL)発症の分子機構 日本臨床 73:168-171 (2015)
Saito Y, Morishita K. Maintenance of leukemic and normal hematopoietic stem cells in bone marrow niches by EVI1-regulated GPR56. Rinsho Ketsueki. 2015 Apr;56(4):375-83.
中畑新吾、森下和広：ATLL発症機構解析研究の進歩 血液内科 71:244-249 (2015)
Nakahata S, Morishita K. PP2A inactivation by ROS accumulation. Blood. 2014 Oct 2;124(14):2163-5.
Nakahata S, Morishita K. CADM1/TSLC1 is a novel cell surface marker for adult T-cell leukemia/lymphoma. J Clin Exp Hematop. 2012;52(1):17-22.
中畑新吾、森下和広：HTLV-1によるATLLの発症機序 血液内科 63:389-398 (2011)
中畑新吾、森下和広：ATLの発症機構 Annual Review血液132-138 (2010)
Morishita K. Role of CtBP-binding transcription factors in leukemogenesis. Rinsho Ketsueki. 2009 Mar;50(3):160-7.
中畑新吾、森下和広：TCF8遺伝子発現抑制による成人T細胞白血病・リンパ腫発症機構 血液フロンティア 18;65-72 (2008)
Morishita K. Leukemogenesis of the EVI1/MEL1 gene family. Int J Hematol. 2007 May;85(4):279-86.
Matsuda Z, Iga M, Miyauchi K, Komano J, Morishita K, Okayama A, Tsubouchi H. In vitro translation to study HIV protease activity. Methods Mol Biol. 2007;375:135-49.
森下和広: ATLに対する新たな分子マーカーTSLC1 HTLV-1と疾患 文公堂 186-187 (2007)
森下和広：ATLに対する新たな分子マーカーTSLC1 血液・腫瘍科 Hematology & Oncology 50(6);592-598 (2005)
森下和広：ウイルス感染、ゲノム異常と白血病発症機構 宮崎医学会誌 29(1);1-7 (2005)
森下和広、横田 淳：染色体相互転座を指標とした病因遺伝子の単離 臨床遺伝学 97;236-242 (1997)
森下和広：evi-1 BioScience 用語ライブラリー 癌遺伝子癌抑制遺伝子74–75 (1997)
森下和広：Myc遺伝子ファミリー メディカル用語ライブラリー 癌 27- 31 (1996)
森下和広：Oncogenic conversion of transcriptional factors in leukemias (転写因子異常と白血病) Molecular Medicine (Japan) 32;510-517 (1995)
森下和広：Oncogenic transversion of transcriptional factor in acute leukemia (白血病における転写因子の意義) Annual Review 血液 104-114 (1994)
森下和広：A novel signal transduction pathway under the cytokine receptor superfamily (サイトカインレセプターの下流に新しく見つけられた情報伝達系) Experimental Medicine (実験医学) 12:63-67 (1994)
Tani K, Morishita K, Fukuhara S, Inoue T, Kobayashi Y, Asano S. Molecular analysis of leukemia and lymphoma. The role of molecular biology in clinical medicine 1993;1:108-114.
森下和広：Interleukin 3 BIOmedica (Japan) 8:717-721 (1993)
森下和広：Oncogenic transcription factors in hematological malignancies（白血病における転写因子の意義） SAISHIN-IGAKU 最新医学 (Japan) 48:19-27 (1993)
Ihle JN, Morishita K, Bartholomew C, Matsugi T, Askew D. Phenotypes and mechanisms in the transformation of hematopoietic cells. Int J Cell Cloning. 1990 Jan;8 Suppl 1:130-46.
森下和広：Function of IL-3 and the relationship to myeloid transformation（IL-3の機能と白血病化に対する影響） J Clin Sci 臨床科学 (Japan) 26:1074-1082 (1990)
森下和広：Signal transduction and function of the IL-3（IL-3の情報伝達系とその機能） Metabolism and Disease 代謝 (Japan) 27:878-887 (1990)
Ihle JN, Morishita K, Matsugi T, Bartholomew C. Insertional mutagenesis and transformation of hematopoietic stem cells. Prog Clin Biol Res. 1990;352:329-37.
Morishita K and Ihle JN. Mechanisms in the growth, differentiation and transformation of interleukin-3 regulated hematopoietic stem cells. Experimetal Medicine 実験医学 (Japan) 7:1720-1736 (1989)
Ihle JN, Morishita K, Isfort R, Bartholomew C, Askew D, Cleveland J, and Weinstein Y. Mechanisms in interleukin-3 regulated growth and differentiation of hematopoietic stem cells. In: Mochida Memorial Foundation for Medical and Pharmaceutical Research. 91-118 (1989)
Ihle JN, Morishita K, Isfort R, Bartholomew C, Askew D, Cleveland J, and Weinstein Y. Mechanisms in interleukin-3 regulated growth and differentiation of hematopoietic stem cells. In: Cell Biology: NATO Advanced Study Series 331-341 (1989)
Ihle JN, Morishita K, Parker DS, Bartholomew C, Askew D, Buckberg A, Jenkins N, Copeland N, and Weinstein Y. Mechanisms in the transformation of IL-3 dependent hematopoietic stem cells. Curr Top Microbiol Immunol 149:59-69 (1989)
症例報告
Morishita K, Kodo H, Asano S, Fujii H, Miwa S. Fulminant varicella hepatitis following bone marrow transplantation. JAMA. 1985 Jan 25;253(4):511.
Morishita K, Fujii H, Asano S, Fujimaki M, Miwa S. A case of hereditary spherocytosis associated with factor V deficiency. Nihon Ketsueki Gakkai Zasshi. 1983 Feb;46(1):208-11.
Morishita K, Ieki R, Iwata K, Fujii H, Asano S, Miwa S, Wakabayashi T, Furuta T. Three cases of pneumocystis carinii pneumonia associated with hematological disorders. Rinsho Ketsueki. 1982 Jul;23(7):1089-95.
特許
1.
出願番号：2003-384089
出願日：2003年11月13日
出願人・特許権者：㈱みやざきTLO
発明者：森下和広、坪内博仁、村上善則
発明の名称 成人Ｔ細胞白血病診断薬
2.
出願番号：2005-032117
出願日：2005年2月8日
出願人・特許権者：JST
発明者：山崎正夫、水光正仁、坪内博仁、森下和広
発明の名称 成人Ｔ細胞白血病の予防剤または治療剤（大豆イソフラボン）
3.
出願番号：2005-138388
出願日：2005年5月11日
出願人・特許権者：㈱みやざきTLO、（㈱ケージーエス）
発明者 森下和広、小林行治
発明の名称 成人Ｔ細胞白血病の診断器具
4.
出願番号：2005-150813
出願日：2005年5月24日
出願人・特許権者：宮崎大学、JST
発明者 森下和広、坪内博仁、谷脇雅史
発明の名称：Ｔリンパ性白血病の検出方法及び検出用キット（AREB6）
5.
出願番号：特願2005-54624 国際公開番号：WO/2006/090750
出願日：2005年2月28日
出願人・特許権者：抗体研究所
発明者 黒澤良和、鵜飼由範、森下和広、他
発明の名称 抗IgSF4抗体及びその利用
6.
出願番号：2007-86749
出願日：2007年3月29日
出願人・特許権者：宮崎県、JST、宮崎大学
発明者：岡山昭彦、森下和広、坪内博仁、石田洋一
発明の名称：成人Ｔ細胞白血病マーカー
7.
出願番号：特願2007-093469
出願日：2007年03月30日
出願人・特許権者：国立大学法人 宮崎大学、宮崎県、財団法人宮崎県産業支援財団
発明者：清水 正高、西片 奈保子、森下 和広、山川 哲生、酒井 美穂
発明の名称：物質を細胞内へ導入するために用いるエマルション及びそれを用いた物質導入方法
8.
出願番号：特願2008-031855
出願日：2008年02月13日
出願人・特許権者：国立大学法人 宮崎大学、財団法人宮崎県産業支援財団
発明者：森下 和広、谷脇 雅史、濱崎 誠
発明の名称：細胞接着阻害剤およびその用途ヒトT細胞白血病ウイルス感染あるいは成人T細胞白血病発症の検出法、その診断薬、ならびにその予防および治療の為の薬剤
9.
出願番号：特願2011-508324
出願日：2010年03月26日
出願人・特許権者：国立大学法人 宮崎大学、公益財団法人宮崎県産業振興機構
発明者：森下 和広、中畑 新吾、濱崎 誠
発明の名称：PTENのリン酸化抑制剤又は脱リン酸化剤
10.
出願番号：特願2011-501535
出願日：2010年01月28日
出願人・特許権者：国立大学法人 宮崎大学
発明者：森下 和広、山川 哲生
発明の名称：細胞接着阻害剤およびその用途
11.
出願番号：特願2011-193331
出願日：2011年08月18日
出願人・特許権者：国立大学法人 宮崎大学
発明者：福田 健太、小林 行治、中武 彩子、森下 和広、谷口 喬子
発明の名称：成人T細胞白血病診断器具
12.
出願番号：特願2013-515140
出願日：2012年05月11日
出願人・特許権者：国立大学法人 宮崎大学
発明者：森下 和広、齋藤 祐介
発明の名称：細胞接着阻害剤、細胞増殖阻害剤、並びに癌の検査方法および検査用キット
13.
出願番号：特願2014-545766
出願日：2013年11月08日
出願人・特許権者：国立大学法人 宮崎大学、株式会社ペルセウスプロテオミクス
発明者：黒澤 良和、森下 和広、張 黎臨、黒澤 仁、見供 克之、須藤 幸夫、野村 富美子、鵜飼 由範
発明の名称：トランスフェリン受容体を特異的に認識できる抗体
14.
出願番号：特願2014-109037
出願日：2014年5月27日
出願人・特許権者：宮崎大学、学校法人藤田学園、株式会社ペルセウスプロテオミクス
発明者：森下 和広、黒澤 良和、黒澤 仁、須藤 幸夫、張 黎臨
発明の名称：IgSF4/TSLC1/CADM1を特異的に認識できる抗体
15.
国際出願番号：PCT/JP2010/055378 国際公開番号：WO2010/116899
特許第5517078号 登録日 2014年4月11日
出願人・特許権者：宮崎大学
発明者：森下和広、中畑新吾、濱崎誠
発明の名称：PI3K/AKT情報伝達系に関連する疾病の予防薬、進展抑制薬、または治療薬、発明者
16.
国際出願番号：PCT/JP2014/061548
出願日：2014年4月24日
出願人・特許権者：宮崎大学
発明者：森下和広、市川朝永、中畑新吾
発明の名称：成人T細胞白血病の診断方法および成人T細胞白血病の治療薬のスクリーニング方法
17.
出願番号：特願2016-059197
出願日：2016年03月23日
出願人・特許権者：国立大学法人 宮崎大学、永瀬 浩喜
発明者：森下 和広、兼田 加珠子、齋藤 祐介、永瀬 浩喜
発明の名称：化合物またはその塩および医薬組成物
